ATLANTA — The CDC’s Advisory Committee on Immunization Practices (ACIP) voted in favor of including the new 9-valent HPV strain vaccine in its recommendations about HPV immunization.

And in other votes at the weather-shortened meeting here, the panel voted to recommend meningococcal group B vaccines only for high-risk groups, including individuals in “outbreak areas,” and dialed back its recommendation of the live attenuated influenza vaccine (LAIV) to “no preference” compared to the inactive vaccine.

HPV Products

Continue Reading

The 9-valent HPV strain vaccine (Gardasil-9) was licensed in December for use in females ages 9 to 26 and males ages 9 to 15. The new vaccine targets five additional strains of HPV, which adds protection against 14% of additional HPV cancers in women and 5% additional HPV cancers in men. The committee reviewed clinical trials showing the efficacy of the 9-valent HPV vaccine was about 97% compared with the current 4-valent HPV vaccine, and it was more cost-effective as well.

READ FULL ARTICLE Curated publisher From Medical Page Today